Expanding Products and Services Focused on Human Cells
First written in FY2017-Q1. 20 of 30 entries say "Restated". Latest entry: 2026-10-09.
3 other companies' latest entry also says "Advanced".
- 2026-10-09AdvancedOther Disclosures
「REPROSKIN™は、当社独自の三次元培養技術である Alvetex®技術を基盤に、英国ダーラム大学との研究開発によって生み出されたヒト全層皮膚モデルです。」
ヒト由来細胞を用いた全層皮膚モデルの販売開始により、ヒト細胞に特化した製品・サービスが具体的に拡充した。 - FY2026-H1AdvancedAnnual report
「This product will accelerate research and development of universal donor cells, which are intended to address the major challenge of immune rejection in cell-transplantation therapies using allogeneic iPS cells.」
As part of the expansion of human iPS cell-related products, the company began selling products for universal donor cell development aimed at addressing immune rejection. - FY2025-H1AdvancedAnnual report
「In July 2024, we launched iPS cell-derived exosomes and entered into an agreement appointing JTB Corporation (hereinafter, "JTB") as the exclusive distributor.」
As part of the expansion of products and services focused on human cells, the company launched sales of exosomes derived from iPS cells, beginning distribution through JTB. - FY2024AdvancedAnnual report
「In January 2024, we newly launched a business involving mesenchymal stem cells derived from human iPS cells (hereinafter, “iPSC-MSC”).」
As part of the expansion of products and services focused on human cells, the company launched its iPSC-MSC business and expanded its lineup. - FY2024-Q3AdvancedAnnual report
「In December 2023, we entered into a distributorship agreement with Preci (Ukraine) and began selling primary human hepatocytes in Japan.」
For its product line focused on human cells, the company began domestic sales of primary human hepatocytes, expanding its range of human cell products. - FY2024-Q2RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions.」
The company has reaffirmed its human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2024-Q1RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions.」
The company has reaffirmed its human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2023-Q3RestatedAnnual report
「By making maximum use of this technologically advanced human-cell business platform, we are pursuing a business that anticipates the aforementioned shift from animal testing to testing with human cells.」
The company has reaffirmed its policy of utilizing a human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2023-Q2RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions.」
The company has reaffirmed its human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2023-Q1RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions.」
The company has reaffirmed its human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2022-Q3RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions. By making maximum use of this technologically advanced human-cell business platform, we are pursuing a business that anticipates the aforementioned shift from animal testing to testing with human cells.」
The company has reaffirmed its policy of utilizing a human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2022-Q1RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions.」
The company has reaffirmed its human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2021RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions.」
The company has reaffirmed its human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2021-Q3RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including third-generation RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions.」
The company has reaffirmed its human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2021-Q2RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including third-generation RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions.」
The company has reaffirmed its human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2021-Q1RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including third-generation RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions.」
The company has reaffirmed its human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2020RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including third-generation RNA reprogramming technology and technologies for inducing differentiation into various cell types, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions.」
The company has reaffirmed its human-cell business platform combining iPS cell technology, differentiation-induction technology, and a sourcing network for cancer cells and human tissues. - FY2020-Q3RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including third-generation RNA reprogramming technology, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions. By making maximum use of this technologically advanced human-cell business platform, we are pursuing a business that anticipates the aforementioned shift from animal testing to testing with human cells.」
The company has reaffirmed its policy of utilizing a human-cell business platform that combines third-generation RNA reprogramming technology with a sourcing network for cancer cells and human tissues. - FY2020-Q2RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including third-generation RNA reprogramming technology, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions. By making maximum use of this technologically advanced human-cell business platform, we are pursuing a business that anticipates the aforementioned shift from animal testing to testing with human cells.」
The company has reaffirmed its policy of developing its human-cell business by combining third-generation RNA reprogramming technology with a sourcing network for cancer cells and human tissues. - FY2020-Q1RestatedAnnual report
「The Group has a world-leading technology platform related to human iPS cells, including third-generation RNA reprogramming technology, as well as an extensive network for sourcing cancer cells and human tissues from medical institutions. By making maximum use of this technologically advanced human-cell business platform, we are pursuing a business that anticipates the aforementioned shift from animal testing to testing with human cells.」
The company has reaffirmed its policy of developing its human-cell business by combining third-generation RNA reprogramming technology with a sourcing network for cancer cells and human tissues. - FY2019-Q3AdvancedAnnual report
「We also successfully developed sensory nerve cells derived from human iPS cells jointly with FANCL CORPORATION and launched a contract manufacturing service in October 2018.」
The company states that it successfully developed sensory nerve cells derived from human iPS cells jointly with FANCL CORPORATION and launched a contract manufacturing service in October 2018. - FY2019-Q2RestatedAnnual report
「We have also assembled a broader lineup of human cells by directly collecting from people cancer cells and human tissues that are difficult to produce from human iPSCs. By offering a broad range of human iPSCs and human tissues in this way, we will further enhance our competitive advantage.」
The company has reaffirmed its broad lineup of human cells, including human iPS cells, directly harvested cancer cells and human tissues, as well as the resulting competitive advantage. - FY2019-Q1RestatedAnnual report
「In addition, we offer a broader lineup of human cells by directly harvesting from humans cancer cells and human tissues that are difficult to create from human iPS cells.」
The company continues to maintain a lineup of human cells that includes human iPS cells, directly harvested cancer cells and human tissues. - FY2018AdvancedAnnual report
「The Group will further strengthen its competitive advantage by maintaining a broad range of human iPS cells and human tissues.」
The company has indicated a policy of maintaining a lineup that includes human iPS cells, directly harvested cancer cells and human tissues, while also expanding cell sourcing in India and drug discovery support services. - FY2018-Q3RestatedAnnual report
「We have also assembled a broader lineup of human cells by directly collecting from people cancer cells and human tissues that are difficult to produce from human iPSCs. By offering a broad range of human iPSCs and human tissues in this way, we will further enhance our competitive advantage.」
The company has reiterated its commitment to maintaining a range of human cell products and services combining human iPS cells and human tissues, thereby strengthening its competitive advantage. - FY2018-Q1RestatedAnnual report
「We have also assembled a broader lineup of human cells by directly collecting from people cancer cells and human tissues that are difficult to produce from human iPSCs. By offering a broad range of human iPSCs and human tissues in this way, we will further enhance our competitive advantage.」
The company has reaffirmed its policy of maintaining a broad lineup of human cells, including human iPS cells as well as directly harvested cancer cells and human tissues. - FY2017RestatedAnnual report
「Pharmaceutical companies worldwide have been making a major shift from animal testing to testing with human cells. In response to this trend, the Group is strengthening its human-cell technologies and expanding its product lineup.」
The company continues to pursue its policy of strengthening products and services focused on human cells and expanding its lineup. - FY2017-Q3AdvancedAnnual report
「During the nine-month period under review, we entered into an agreement with FANCL CORPORATION regarding the development of model cells derived from human iPS cells. Going forward, we will create and provide cells derived from iPS cells in accordance with FANCL CORPORATION's requirements.」
For the provision of human cells and services to businesses, the company entered into an agreement with FANCL CORPORATION to develop model cells. - FY2017-Q2AdvancedAnnual report
「As a new service, we launched contract services using next-generation RNA reprogramming technology to create iPS cells from cells found in urine, and have received interest from various companies.」
In line with its existing policy of providing human cells and related services, the company launched a contract service to create iPS cells from cells found in urine. - FY2017-Q1First statedAnnual report
「The Group differentiates itself from competitors by offering both cell sales and services to address a broad range of customer needs. It also maintains an extensive range of human cells, including iPS cells, and is strengthening its competitive advantage by focusing on human cells.」
A business model that supports drug discovery research by pharmaceutical and chemical companies through a combination of cell product sales and contract research services.